NASDAQ:ARWR

Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

$32.42

-1.15 (-3.43%)

(As of 10/7/2022 11:46 AM ET)

Add

Compare

Today's Range: $32.26
▼
$33.21
50-Day Range: $29.63
▼
$48.31
52-Week Range: $26.81
▼
$84.83

Volume: 5,391 shs
Average Volume: 892,769 shs
Market Capitalization: $3.43 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $66.57

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 105.3% Upside
$66.57 Price Target
Short Interest: Bearish
4.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.57
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.29) to ($1.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

900th out of 1,075 stocks

Pharmaceutical Preparations Industry

440th out of 537 stocks

3.3

Analyst's Opinion

Consensus Rating
Arrowhead Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $66.57, Arrowhead Pharmaceuticals has a forecasted upside of 105.3% from its current price of $32.42.
Amount of Analyst Coverage
Arrowhead Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.17% of the float of Arrowhead Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Arrowhead Pharmaceuticals has recently increased by 1.91%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Arrowhead Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

3.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Arrowhead Pharmaceuticals has received a 44.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "RNA interference medication for cancer", "Cardiovascular siRNA medication", and "Liver-disease medication (A05)" products. See details.
Environmental Sustainability
The Environmental Impact score for Arrowhead Pharmaceuticals is -2.57.

0.0

News and Social Media Coverage

Search Interest
Only 3 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.
Percentage Held by Institutions
67.29% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($1.29) to ($1.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arrowhead Pharmaceuticals is -21.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arrowhead Pharmaceuticals is -21.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arrowhead Pharmaceuticals has a P/B Ratio of 8.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

August 6, 2022 | benzinga.com

Arrowhead Pharmaceuticals: Q3 Earnings Insights

August 4, 2022 | finance.yahoo.com

Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

July 20, 2022 | finance.yahoo.com

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results

July 1, 2022 | seekingalpha.com

My 26 Stock $336k Portfolio Outperforms The Market In Horrendous June Because Of This Key Trade

June 30, 2022 | nasdaq.com

5 Top Biotech Stocks To Watch In July 2022

June 28, 2022 | seekingalpha.com

Arrowhead Pharma: We Can Afford To Wait For More Proof

June 27, 2022 | bizjournals.com

MilliporeSigma opens $65 million facility in Verona

June 27, 2022 | finance.yahoo.com

Drug reduces mutant protein that can lead to fibrosis in rare genetic liver disease

June 16, 2022 | finance.yahoo.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Is In A Strong Position To Grow Its Business

June 16, 2022 | nasdaq.com

Relative Strength Alert For Arrowhead Pharmaceuticals

May 10, 2022 | investing.com

Arrowhead Pharmaceuticals Inc. Tops Q2 EPS by 44c

May 9, 2022 | bizjournals.com

Arrowhead breaks ground on up to $250M Verona project, will receive incentives

May 2, 2022 | finance.yahoo.com

Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences

May 2, 2022 | apnews.com

Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors

April 26, 2022 | seekingalpha.com

Arrowhead begins dosing in phase 2 trial of ARO-ANG3 to treat cholesterol disorder

April 26, 2022 | finance.yahoo.com

Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia

April 14, 2022 | seekingalpha.com

Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices

March 24, 2022 | seekingalpha.com

Arrowhead Pharmaceuticals asks regulators to begin early-stage asthma trial

February 24, 2022 | finance.yahoo.com

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

February 18, 2022 | finance.yahoo.com

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

February 17, 2022 | finance.yahoo.com

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

January 24, 2022 | finance.yahoo.com

Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline

January 20, 2022 | benzinga.com

Goldman Sachs Upgrades Arrowhead Pharmaceuticals to Buy

January 12, 2022 | seekingalpha.com

Arrowhead Pharma initiates late-stage ARO-APOC3 study for familial chylomicronemia syndrome

January 12, 2022 | finance.yahoo.com

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings: 8/04/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/28/2022
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARWR
CUSIP: N/A
CIK: 879407
Web: www.arrowheadpharma.com
Phone: (626) 304-3400
Fax: 626-304-3401
Employees: 329
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $66.57
High Stock Price Forecast: $110.00
Low Stock Price Forecast: $36.00
Forecasted Upside/Downside: +105.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-140,850,000.00
Net Margins: -61.58%
Pretax Margin: -61.58%
Return on Equity: -36.05%
Return on Assets: -21.96%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 3.37
Quick Ratio: 3.37

Sales & Book Value

Annual Sales: $138.29 million
Price / Sales: 24.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.92 per share
Price / Book: 8.27

Miscellaneous

Outstanding Shares: 105,850,000
Free Float: 102,144,000
Market Cap: $3.43 billion
Optionable: Optionable
Beta: 1.44

Key Executives

Dr. Christopher R. Anzalone Ph.D. (Age 53)
CEO, Pres & Director
Comp: $1.68M

Mr. Kenneth A. Myszkowski (Age 56)
Chief Financial Officer
Comp: $729.77k

Mr. Patrick O'Brien J.D. (Age 58)
PharmD, COO & Gen. Counsel
Comp: $733.13k

Dr. James C. Hamilton M.D. (Age 43)
MBA, Sr. VP of Discovery & Translational Medicine
Comp: $673.45k

Dr. Javier San Martin M.D. (Age 57)
Chief Medical Officer
Comp: $658.48k

Dr. Mark M. Davis Ph.D.
Founder and Founder & Director of Insert Therapeutics Inc & Calando

Ms. Jane Davidson
Head of HR & Admin., VP and Corp. Sec.

Dr. Vincent Anzalone CFA
Head of Investor Relations & VP

Mr. Howard Lovy
Director of Communications

Dr. Mark Seefeld (Age 68)
Head of Toxicology & VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings or view top-rated stocks.
What is Arrowhead Pharmaceuticals' stock price forecast for 2022?: 6 Wall Street analysts have issued 12 month target prices for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $36.00 to $110.00. On average, they expect the company's stock price to reach $66.57 in the next year. This suggests a possible upside of 98.3% from the stock's current price.
View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts.
How have ARWR shares performed in 2022?: Arrowhead Pharmaceuticals' stock was trading at $66.30 at the beginning of the year. Since then, ARWR stock has decreased by 49.4% and is now trading at $33.57.
View the best growth stocks for 2022 here.
When is Arrowhead Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our ARWR earnings forecast.
How were Arrowhead Pharmaceuticals' earnings last quarter?: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.17. The biotechnology company earned $32.41 million during the quarter, compared to analyst estimates of $52.61 million. Arrowhead Pharmaceuticals had a negative net margin of 61.58% and a negative trailing twelve-month return on equity of 36.05%. Arrowhead Pharmaceuticals's quarterly revenue was down 29.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.29) earnings per share.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).
What is Arrowhead Pharmaceuticals' stock symbol?: Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How do I buy shares of Arrowhead Pharmaceuticals?: Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arrowhead Pharmaceuticals' stock price today?: One share of ARWR stock can currently be purchased for approximately $33.57.
How much money does Arrowhead Pharmaceuticals make?: Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $3.55 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140,850,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.
How many employees does Arrowhead Pharmaceuticals have?: The company employs 329 workers across the globe.
How can I contact Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

Arrowhead Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month